Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia

Bone

Volumn 26, Issue 2, 2000, Pages 175-182

  Ishii, H ^a   Wada, M ^a   Furuya, Y ^a   Nagano, N ^a   Nemeth, E F ^b   Fox, J ^b  

^a KIRIN BREWERY CO LTD   (Japan)

^b NPS Pharmaceutical Inc   (United States)

Author keywords

Adriamycin; Ca2+ receptor; Calcimimetics; Parathyroid hormone; Renal osteodystrophy; Secondary hyperparathyroidism

Indexed keywords

CALCIFEDIOL; CALCITRIOL; CALCIUM; CREATININE; DOXORUBICIN; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE LESION; BONE MINERAL; BONE TURNOVER; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; MALE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOMALACIA; RAT; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; UREMIA;

ANILINE COMPOUNDS; ANIMALS; BONE AND BONES; BONE DENSITY; CALCIUM; DISEASE MODELS, ANIMAL; DOXORUBICIN; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; OSTEOMALACIA; PARATHYROID HORMONE; PHOSPHATES; RATS; RATS, SPRAGUE-DAWLEY; RENAL OSTEODYSTROPHY; UREMIA;

EID: 0033962371     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(99)00263-X     Document Type: Article

References (49)

1. Akizawa T., Suzuki M., Tominaga Y., Saito A., Uchida E., Kawaguchi Y., Ogata E., Kurokawa K. Acute effect of calcimimetic agent (CA) on hemodialysis (HD) patients with secondary hyperparathyroidism (2HPT) [Abstr.]. J Am Soc Nephrol. 9:1998;561.
2. Antonsen J.E., Sherrard D.J. Renal osteodystrophy past and present . Semin Dialysis. 9:1996;296-302.
3. Antonsen J.E., Sherrard D.J., Andress D.L. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int. 53:1998;223-227.
4. Bover J., Jara A., Trinidad P., Rodriguez M., Martin-Malo A., Felsenfeld A.J. The calcemic response to PTH in the rat effect of elevated PTH levels and uremia . Kidney Int. 46:1994;310-317.
5. 2+-sensing receptor from bovine parathyroid. Nature. 366:1993;575-580.
6. Crowell J.A. Jr, Cooper C.W., Toverud S.U., Boass A. Influence of vitamin D on parathyroid hormone-induced adenosine 3′,5′-monophosphate production by bone cells isolated from rat calvariae. Endocrinology. 109:1981;1715-1722.
7. Dempster D.W., Cosman F., Parisien M., Shen V., Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocrin Rev. 14:1993;690-709.
8. Fournier A., Yverneau P., Hué P., Said S., Hamdini N., Mohy Eldin H., Mohageb S., Oprisiu R., Marie A., Solal M.E., Morinière P. Adynamic bone disease in patients with uremia. Curr Opin Nephrol Hypertens. 3:1994;396-410.
9. Fox J., Lowe S.H., Petty B.A., Nemeth E.F. NPS R-568 a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium . J Pharmacol Exp Therapeut. 290:1999;473-479.
10. Fox J., Lowe S.H., Conklin R.A., Nemeth E.F. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrine. 10:1999;97-103.
11. Fox J., Miller M.A., Conklin R.L., Lowe S.H., Petty B.A., Nemeth E.F. The calcimimetic NPS R-568 prevents the development of secondary hyperparathyroidism and elevated bone formation in rats with mild chronic renal insufficiency [Abstr.]. J Bone Miner Res. 10:(Suppl. 1):1995;191.
12. Fox J., Miller M.A., Stroup G.B., Nemeth E.F., Miller S.C. Plasma levels of parathyroid hormone that induce anabolic effects in bone of ovariectomized rats can be achieved by stimulation of endogenous hormone secretion. Bone. 21:1997;163-169.
13. Friedlaender G.E., Tross R.B., Doganis A.C., Kirkwood J.M., Baron R. Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Surg. 66:1984;602-607.
14. House M.G., Kohlmeier L., Chattopadhyay N., Kifor O., Yamaguchi T., LeBoff M.S., Glowacki J., Brown E.M. Expression of an extracellular calcium-sensing receptor in human and mouse bone marrow cells. J Bone Miner Res. 12:1997;1959-1970.
15. Galceran T., Martin K.J., Morrissey J.J., Slatopolsky E. Role of 1,25-dihydroxyvitamin D in the skeletal resistance to parathyroid hormone. Kidney Int. 32:1987;801-807.
16. Heath H. III, Sanguinetti E.L., Oglesby S., Marriott T.B. Inhibition of human parathyroid hormone secretion in vivo by NPS R-568, a calcimimetic drug that targets the parathyroid cell-surface calcium receptor [Abstr.]. Bone. 16:(Suppl. 1):1995;85.
17. Kimmel D.B., Bozzato R.P., Kronis K.A., Coble T., Sindrey D., Kwong P., Recker R.R. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology. 132:1993;1577-1584.
18. Llach F., Bover J. Renal osteodystrophy. Brenner B.M. The Kidney. 1996;2187-2273 W.B. Saunders, Philadelphia.
19. Malluche H.H., Faugere M.-C. Renal bone disease 1990 an unmet challenge for the nephrologist . Kidney Int. 38:1990;193-211.
20. Malluche H.H., Matthews C., Faugere M.-C., Fanti P., Endres D.B., Friedler R.M. 1,25-Dihydroxyvitamin D maintains bone cell activity, and parathyroid hormone modulates bone cell number in dogs. Endocrinology. 119:1986;1298-1304.
21. Malluche H.H., Sherman D., Meyer W., Massry S.G. A new semiautomatic method for quantitative static and dynamic bone histology. Calcif Tissue Int. 34:1982;439-448.
22. Malluche H.H., Sherman D., Meyer W., Ritz E., Norman A.W., Massry S.G. Effects of long-term infusion of physiologic doses of 1-34 PTH on bone. Am J Physiol. 242:1982;F197-F201.
23. Manaka R.C., Malluche H.H. A program package for quantitative analysis of histologic structure and remodeling dynamics of bone. Comput Programs Biomed. 13:1981;191-201.
24. Massry S.G., Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol. 14:1994;219-231.
25. Miller M.A., Fox J. Daily transient decreases in plasma PTH levels induced by the calcimimetic NPS R-568 slows the rate of bone loss, but does not increase bone mass in ovariectomized rats [Abstr.]. J Bone Miner Res. 14:(Suppl. 1):1999;430.
26. Mitchell J., Tenenhouse A., Warner M., Goltzman D. Parathyroid hormone desensitization in renal membranes of vitamin D-deficient rats is associated with a postreceptor defect. Endocrinology. 122:1988;1834-1841.
27. 2+ receptor-dependent regulation of cellular functions. News Physiol Sci. 10:1995;1-5.
28. Nemeth E.F. Calcium receptors as novel drug targets. Bilezikian J.P., Raisz L.G., Rodan G.A. Principles of Bone Biology. 1996;1019-1035 Academic Press, San Diego.
29. Nemeth E.F., Steffey M.E., Hammerland L.G., Hung B.C.P., VanWagenen B.C., DelMar E.G., Balandrin M.F. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA. 95:1998;4040-4045.
30. Okuda S., Oh Y., Tsuruda H., Onoyama K., Fujimi S., Fujishima M. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int. 29:1986;502-510.
31. Parfitt A.M. Drug-induced osteomalacia. Favus M.J. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2nd ed. 1993;296-300 Raven, New York.
32. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., Ott S.M., Recker R.R. Bone histomorphometry standardization of nomenclature, symbols, and units . J Bone Miner Res. 2:1987;595-610.
33. Pei Y., Hercz G. Low turnover bone disease in dialysis patients. Semin Dialysis. 9:1996;327-331.
34. Quarles L.D. Cation sensing receptors in bone a novel paradigm for regulating bone remodeling? J Bone Miner Res. 12:1997;1971-1974.
35. Riggs B.L., Melton L.J. III. The prevention and treatment of osteoporosis. N Engl J Med. 327:1992;620-627.
36. Rodriguez M., Felsenfeld A.J., Llach F. Calcemic response to parathyroid hormone in renal failure role of calcitriol and the effect of parathyroidectomy . Kidney Int. 40:1991;1063-1068.
37. Salusky I.B., Goodman W.G. Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy. Kidney Int. 48:1995;657-665.
38. Sherrard D.J., Hercz G., Pei Y., Maloney N.A., Greenwood C., Manuel A., Saiphoo C., Fenton S.S., Segre G.V. The spectrum of bone disease in end-stage renal failure an evolving disorder . Kidney Int. 43:1993;436-442.
39. Silver J., Naveh-Many T. Regulation of parathyroid hormone synthesis and secretion. Semin Nephrol. 14:1994;175-194.
40. Silverberg S.J., Bone H.G. III, Marriott T.B., Locker F.G., Thys-Jacobs S., Dziem G., Kaatz S., Sanguinetti E.L., Bilezikian J.P. Short-term inhibition of parathyroid hormone secretion by a calcium receptor agonist in patients with primary hyperparathyroidism. N Engl J Med. 337:1997;1506-1510.
41. Slatopolsky E., Delmez J.A. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 23:1994;229-236.
42. Slatopolsky E., Burke S.K., Dillon M.A. RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int. 55:1999;66-71.
43. Turner G., Coureau C., Rabin M., Escoubet B., Hruby M., Walrant O., Silve C. Parathyroid hormone (PTH)/PTH-related protein receptor messenger ribonucleic acid expression and PTH response in a rat model of secondary hyperparathyroidism associated with vitamin D deficiency. Endocrinology. 136:1995;3751-3758.
44. 3. Arch Intern Med. 143:1983;1205-1211.
45. Wada M., Furuya Y., Sakiyama J.-I., Kobayashi N., Miyata S., Ishii H., Nagano N. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency control of parathyroid cell growth via a calcium receptor . J Clin Invest. 100:1997;2977-2983.
46. Wada M., Ishii H., Furuya Y., Fox J., Nemeth E.F., Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int. 53:1998;448-453.
47. Whitfield J.F., Morley P. Small bone-building fragments of parathyroid hormone new therapeutic agents for osteoporosis . Trends Pharmacol Sci. 16:1995;382-386.
48. Wronski T.J., Yen C.-F., Q H., Dann L.M. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology. 132:1993;823-831.
49. o)-sensing receptor in the clonal osteoblast-like cell lines UMR-106 and SAOS-2. Biochem Biophys Res Commun. 243:1998;753-757.